Volume 25, Issue 2 (March-April 2026)
Payesh 2026, 25(2): 165-177 |
Back to browse issues page
Ethics code: IR.TUMS.SPH.REC.1401.220
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mousavi M, Mosadeghrad A M, Shariatifar N, Jaafaripooyan E. Implementation of Drug Subsidy program: challenges and solutions. Payesh 2026; 25 (2) :165-177
URL: http://payeshjournal.ir/article-1-2682-en.html
URL: http://payeshjournal.ir/article-1-2682-en.html
1- Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Environmental Health Engineering, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2- Department of Environmental Health Engineering, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Abstract: (83 Views)
Objective(s): The "Drug Subsidy" plan, implemented by the Ministry of Health and Medical Education on July 23, 2022, represents a major reform in pharmaceutical policy in Iran. Given the significance of this national initiative for organizing and improving the country’s pharmaceutical system, understanding the emerging implementation issues and challenges is crucial for achieving its intended goals. Therefore, this study aimed to identify the challenges in implementing this plan at Tehran University of Medical Sciences from the stakeholders’ perspective and to offer solutions.
Methods: This qualitative study was conducted in 2023. Semi-structured interviews were conducted with 23 managers, key informants from Food and Drug and Treatment deputies, health insurance experts, doctors, pharmacists, and technical managers of pharmacies at Tehran University of Medical Sciences, selected through purposive and snowball sampling. Data analysis was performed using thematic analysis assisted with MAXQDA software (version 2020).
Results: The challenges and solutions were categorized into three main areas: Financing (e.g., the limited allocation to the subsidy plan in the national budget bill), implementation (e.g., delays in the clearance of pharmaceutical raw materials due to increased value-added tax), and monitoring and supervision (e.g., the costs associated with monitoring and evaluation).
Conclusion: Although the Drug Subsidy plan marks a pivotal step in reforming currency policies, attaining its objectives requires overcoming existing hurdles. Based on the conducted assessment, securing sustainable and earmarked financial resources, streamlining executive and customs procedures, and strengthening infrastructure and supervisory mechanisms appear essential for the program's improvement and ultimate success.
Methods: This qualitative study was conducted in 2023. Semi-structured interviews were conducted with 23 managers, key informants from Food and Drug and Treatment deputies, health insurance experts, doctors, pharmacists, and technical managers of pharmacies at Tehran University of Medical Sciences, selected through purposive and snowball sampling. Data analysis was performed using thematic analysis assisted with MAXQDA software (version 2020).
Results: The challenges and solutions were categorized into three main areas: Financing (e.g., the limited allocation to the subsidy plan in the national budget bill), implementation (e.g., delays in the clearance of pharmaceutical raw materials due to increased value-added tax), and monitoring and supervision (e.g., the costs associated with monitoring and evaluation).
Conclusion: Although the Drug Subsidy plan marks a pivotal step in reforming currency policies, attaining its objectives requires overcoming existing hurdles. Based on the conducted assessment, securing sustainable and earmarked financial resources, streamlining executive and customs procedures, and strengthening infrastructure and supervisory mechanisms appear essential for the program's improvement and ultimate success.
type of study: Qualitative Study |
Subject:
Helath Services Management
Received: 2024/10/7 | Accepted: 2025/12/22 | ePublished ahead of print: 2026/02/28 | Published: 2026/04/21
Received: 2024/10/7 | Accepted: 2025/12/22 | ePublished ahead of print: 2026/02/28 | Published: 2026/04/21
References
1. Hasan SS, Kow CS, Dawoud D, Mohamed O, Baines D, Babar ZUD. Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific Region: The case of Australia, China, India, Malaysia, New Zealand, and South Korea. Value in Health Regional Issues 2019;18:18-23 [DOI:10.1016/j.vhri.2018.08.007]
2. Guan X, Wushouer H, Yang M, Han S, Shi L, Ross-Degnan D, et al. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open 2019;9:e031658 [DOI:10.1136/bmjopen-2019-031658]
3. Rong X, Yin J, Duan S, Sun Q, Babar ZUD. The effects of pricing policy on the prices and supply of low-cost medicines in Shandong, China: evidence from an interrupted time series analysis. BMC Public Health 2020;20:588 [DOI:10.1186/s12889-020-08746-x]
4. Borghi J, Brown GW. Taking Systems Thinking to the Global Level: Using the WHO Building Blocks to Describe and Appraise the Global Health System in Relation to COVID-19 journal of Global Policy 2022;13:193-207 [DOI:10.1111/1758-5899.13081]
5. Mosadeghrad AM, Khodayari R, Abbasi M, Karimi F. Sustainable financing strategies for the iranian health system: a scoping review journal of School of Public Health and Institute of Public Health Research 2021;19:137-156 [Persian]
6. Ramazani RK. Constitution of the islamic Republic of Iran journal of Middle East 1980;34:181-204 [Persian]
7. Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries journal of Pharmaceutical Sciences 2013;21:52 [Persian] [DOI:10.1186/2008-2231-21-52]
8. Cheraghali AM. Trends in Iran pharmaceutical market journal of Pharmaceutical Research 2017;16:1-7 [Persian]
9. Cheraghali AM, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, et al. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran Journal of Eastern Mediterranean Health 2004;10:406-415 [Persian] [DOI:10.26719/2004.10.3.406]
10. Zarei L, Yousefi N, Azmand S, Joulaei H, Bagheri Lankarani K. The challenges of stopping dual exchange rate in pharmaceutical products and its correction effects in Iran journal of Culture and Health Promotion of Academy of Medical Sciences 2022;5:537-54 [Persian]
11. Wong ZY, Hassali MA, Alrasheedy AA, Saleem F, Yahaya AH, Aljadhey H. Malaysian generic pharmaceutical industries: Perspective from healthcare stakeholders journal of Pharmaceutical Health Services Research 2014;5:193-203 [DOI:10.1111/jphs.12072]
12. Pourasghari H, Saadati M, Moradi N, Rezapour A, Yusefzade N, Dehnad A, Arablou J.Analyzing the policy of allocating preferential currency to medicine and presenting policy options for Iran Health management journal of Halth Administration 2022;25:45-61 [Persian]
13. Atrak Daily. Implementing the Darooyar Project and reforming medicine foreign exchange policies. Atrak Daily 2022 [Available from: https://www.atrakdaily.ir/fa/Main/Detail/28372/]
14. Moj News. Darooyar Project and actions taken in line with it. Moj News 2022 [Available from: https://www.mojnews.com/]]
15. Grossoehme DH. Overview of qualitative research. Health Care Chaplaincy 2014;20:109-122 [DOI:10.1080/08854726.2014.925660]
16. Maggs‐Rapport F. Combining methodological approaches in research:ethnography and interpretive phenomenology journal of Advanced Nursing 2000;31:219-225 [DOI:10.1046/j.1365-2648.2000.01243.x]
17. Braun V, Clarke V. Using thematic analysis in psychology journal of Qualitative Research in Psychology 2006;3:77-101 [DOI:10.1191/1478088706qp063oa]
18. Shenton AK. Strategies for ensuring trustworthiness in qualitative research projects. Educ Inf 2004;22:63-75 [DOI:10.3233/EFI-2004-22201]
19. Lincoln YS, Guba EG. Naturalistic inquiry. 1st Edition, Beverly Hills, CA: Sage Publications; 1985
20. Doshanbehayedarouei.ir. An overview of the challenges of Darooyar Project from the perspective of government media. Doshanbehayedarouei.ir 2023 [Available from: https://doshanbehayedarouei.ir/pharma/12322/]
21. Challenges and Solutions for the Implementation of Darooyar Project journal of Culture and Health Promotion 2023;7:147-149 [Persian]
22. Mohammadinejad Gh. A comparative study of payment systems for hospital services by insurance organizations in several selected countries and providing a suitable model for Iran journal of Health Managemen 2000;6:94-144 [Persian]
23. IRNA. Settlement of the claims of Darooyar project of independent outpatient pharmacies until the end of December. IRNA 2023 [Available from: https://www.irna.ir/news/85008722/]
24. Generic Drug System, an Example of justice in health in the field of pharmaceutical services journal of Culture and Health Promotion 2018;2:423-37 [Persian]
25. Janssen Daalen JM, den Ambtman A, Van Houdenhoven M, van den Bemt BJF. Determinants of drug prices: a systematic review of comparison studies. BMJ Open 2021; 11:e046917 [DOI:10.1136/bmjopen-2020-046917]
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |